Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2022-04-26 Capital/Financing Update
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
투자설명서
Capital/Financing Update Classification · 100% confidence The document is a '투자설명서' (Investment Prospectus) for HLB Life Science Co., Ltd., detailing a capital raise through the issuance of convertible bonds (신주인수권부사채). It includes detailed sections on investment risks, business operations, and financial status, which are standard components of a formal securities registration statement/prospectus. In the context of financial filings, this is classified as a capital/financing update document.
2022-04-26 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from HLB Life Science, specifically detailing a correction (정정신고) to a previously filed report regarding the issuance of bonds with warrants (신주인수권부사채). It outlines changes to maturity dates, interest payment methods, and subscription schedules. In the context of financial filings, reports detailing capital structure changes, such as bond issuances or amendments to their terms, are classified as 'Capital/Financing Update'.
2022-04-14 Korean
[기재정정]증권신고서(채무증권)
Capital/Financing Update Classification · 98% confidence The document is a '증권신고서(채무증권) 정정신고' (Securities Registration Statement (Debt Securities) Amendment). It details specific amendments to a previously filed securities registration statement, including changes to issuance schedules, interest rates, and other terms. This is a formal regulatory filing submitted to the financial authorities (FSS) to correct or update information in a pending securities offering. It fits the 'Regulatory Filings' category as it is a formal amendment to a registration statement.
2022-04-14 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from HLB Life Science, specifically detailing a correction (정정신고) to a previously filed report regarding the issuance of bonds with warrants (신주인수권부사채). It outlines changes to issuance terms, dates, and capital usage. In the context of Korean regulatory filings (DART), this is a standard corporate disclosure regarding capital structure changes, which falls under the 'Share Issue/Capital Change' category.
2022-04-05 Korean
[기재정정]증권신고서(채무증권)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Korean Financial Supervisory Service (FSS). It is a formal regulatory filing detailing a correction (정정신고) to a previously submitted securities registration statement regarding debt securities. It contains detailed financial information, risk factors, and business updates, which are characteristic of a formal regulatory filing rather than a simple announcement or report publication notice. Given the specific nature of the document as a formal regulatory filing for securities, it falls under the 'Regulatory Filings' category.
2022-04-05 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director appointments, and remuneration limits. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2022-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.